PBYI Puma Biotechnology Inc - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 6, 2026
$9.51
· % 处于52周区间
· 高于低点
· 至高点
$4.5852周低点
$10.1052周高点
市值 (MRQ)
$486M
P/E (TTM)
18.3
EPS (TTM)
$0.52
收入 (TTM)
$231M
PBYI 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$9.51
市值 (MRQ)
$486M
P/E (TTM)
18.3
EPS (TTM)
$0.52
收入 (TTM)
$231M
ROE (TTM)
22.0%
负债/权益 (MRQ)
0.0
52周区间
$5–$10
PBYI 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
关于 Puma Biotechnology Inc - Common Stock 公司概况（来自维基百科）
Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.
Creation
Puma was founded in September 2010 by Alan Auerbach to identify and in-license compounds that were already in clinical development. This was the same business plan Auerbach had followed at Cougar Biotechnology, which he founded in 2003, and through which he in-licensed abiraterone acetate from BTG plc. Cougar further developed abiraterone before the company was sold to Johnson & Johnson in 2009. Auerbach brought many Cougar employees with him after founding Puma in 2010.
Funding for development
In August 2011 Puma licensed two drug candidates from Pfizer: neratinib (PB272) and an analog (PB357) to serve as a backup candidate.
As part of an approximately $60 million financing round in October 2011, Puma entered into a reverse merger with the shell company Innovative Acquisitions Corp., formed in 2007. In April 2012 the company's stock began trading over the counter. In October 2012 the company raised around $138 million and its shares were listed on the New York Stock Exchange.
In 2016 Puma discovered that Robert Gadimian, senior director of regulatory affairs, had twice bought and sold stock based on his knowledge of unpublished clinical trial results; Puma quickly fired him after conducting an internal investigation and reported the insider trading to the SEC.
Approval and licensing of neratinib
In March 2016 Puma held a pre-NDA meeting with the FDA in which the FDA raised concerns about the design and conduct of clinical trials that Puma had run and recommended that Puma not file the NDA with that data.
Puma did file the NDA, and in May 2017 an FDA review panel recommended that the FDA approve neratinib but raised concerns that the intended use was too broad and should be limited to people with specific mutations. The FDA's briefing document to the panel had raised concerns about the marginal benefit of the drug and the side effects. In July 2017 the FDA approved neratinib for use in preventing the return of breast cancer after treatment that included trastuzumab and without any need for genetic testing, and with warnings about the risk of severe diarrhea. U.S. sales of neratinib totaled $200.5 million in 2018.
In January 2018 an EMA committee gave a negative review to neratinib. In June 2018 this same EMA committee recommended the approval of neratinib, which received European Commission (EC) approval in September 2018.
In 2019 Puma licensed commercialization rights in Europe and part of Africa to Pierre Fabre for an upfront payment of $60 million and milestone payments that could reach $345 million. Previously, Puma licensed rights in Greater China to CANbrdige Life Sciences, rights in Israel to Medison Pharma, rights in Canada to Knight Therapeutics, rights in South East Asian to Specialised Therapeutics and rights in Latin America to Pint Pharma.
== References ==
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Biotechnology
员工179
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$228M2017-12-31 → 2025-12-31
EPS$0.612020-12-31 → 2025-12-31
自由现金流$42M2016-12-31 → 2025-12-31
净利率11.6%2017-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | PBYI | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | 18.35年均值 ≈5.0 | ≈5.0 | · | · | |
| P/S (TTM) | 2.15年均值 ≈0.8 | ≈0.8 | 7.3 | 低估 | |
| 市净率 (MRQ) | 3.55年均值 ≈-6.8 | ≈-6.8 | 3.0 | 公允价值 | |
| EV / EBITDA (企业价值 / EBITDA) | 11.05年均值 ≈26.1 | ≈26.1 | · | · | |
| 股价/自由现金流 (TTM) | 11.85年均值 ≈2.7 | ≈2.7 | · | · | |
| 市现率 (TTM) | 11.85年均值 ≈2.7 | ≈2.7 | · | · | |
| 市值/营收 (TTM) | 1.75年均值 ≈0.8 | ≈0.8 | · | · | |
| 市值/自由现金流 (TTM) | 9.55年均值 ≈2.1 | ≈2.1 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 5.4 | · | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | PBYI | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | 13.2%5年均值 ≈10.9% | ≈10.9% | -191.1% | 顶尖 | |
| EBITDA Margin (息税折旧摊销前利润率) | 16.3%5年均值 ≈10.9% | ≈10.9% | -184.7% | 顶尖 | |
| 税前利润率 (TTM) | 13.5%5年均值 ≈4.9% | ≈4.9% | -113.8% | 顶尖 | |
| 净利润率 (TTM) | 11.6%5年均值 ≈4.9% | ≈4.9% | -181.7% | 顶尖 | |
| ROA (TTM) | 13.8%5年均值 ≈5.1% | ≈5.1% | -17.8% | 顶尖 | |
| ROE (TTM) | 22.0%5年均值 ≈109.2% | ≈109.2% | -18.7% | 顶尖 | |
| ROIC | 21.2%5年均值 ≈13.5% | ≈13.5% | -22.3% | 顶尖 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | PBYI | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | 0.05年均值 ≈-6.5 | ≈-6.5 | · | · | |
| 流动比率 (MRQ) | 2.95年均值 ≈1.6 | ≈1.6 | 12.6 | 低流动性 | |
| 速动比率 (MRQ) | 2.65年均值 ≈1.5 | ≈1.5 | 2.9 | 低流动性 | |
| 长期负债/股东权益 (MRQ) | 0.05年均值 ≈-6.7 | ≈-6.7 | · | · |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | PBYI | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | -0.91%5年均值 ≈0.56% | ≈0.56% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 0.05%5年均值 ≈-0.50% | ≈-0.50% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 0.29% | · | · | · | |
| EPS YoY | -1.6% | · | · | · | |
| Net Income YoY (净利润同比增长) | 2.8%5年均值 ≈359831.0% | ≈359831.0% | · | · | |
| Net Income CAGR 3Y (净利润年复合增长率（3年）) | 2396.3% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | PBYI | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 1.15年均值 ≈1.0 | ≈1.0 | 0.1 | 顶尖 | |
| Inventory Turnover (库存周转率) | 8.25年均值 ≈9.7 | ≈9.7 | · | · | |
| Receivables Turnover (应收账款周转率) | 5.35年均值 ≈6.3 | ≈6.3 | · | · | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$1.3M | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
171.8%
下次报告
十一月 04, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 5, 2026 | $0.16 | $0.04 | 292.2% |
| 2026年3月31日 | $-0.07 | $-0.13 | 47.2% | |
| 2025年12月31日 | $0.26 | $0.23 | 12.3% | |
| 2025年9月30日 | $0.17 | $0.05 | 270.4% | |
| 2025年6月30日 | $0.12 | $0.10 | 14.6% | |
| 2025年3月31日 | $0.06 | $-0.02 | 394.1% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228M | $230M | $236M | $228M | $253M | $225M | $272M | $251M | $28M | |
| Cost of Revenue | $58M | $64M | $63M | $55M | $64M | $39M | $37M | $35M | $6M | |
| R&D Expense | · | · | · | · | $72M | $98M | $133M | $165M | $208M | |
| SG&A Expense | $71M | $80M | $90M | $90M | $116M | $118M | $142M | $146M | $107M | |
| Operating Expenses | $191M | $200M | $203M | $204M | $252M | $256M | $311M | $346M | $320M | |
| Operating Income | $37M | $31M | $33M | $24M | $1M | $-30M | $-39M | $-95M | $-292M | |
| Interest Expense | · | · | $13M | $12M | $13M | $14M | $15M | $11M | $720.0K | |
| Interest Income | $4M | $5M | $3M | $813.0K | $160.0K | $489.0K | $3M | $2M | $1M | |
| Other Non-op | $1M | $862.0K | $759.0K | $-28.0K | $292.0K | $367.0K | $128.0K | $-714.0K | $-101.0K | |
| Pretax Income | $36M | $24M | $23M | $457.0K | $-29M | $-60M | $-76M | $-114M | · | |
| Income Tax | $5M | $-6M | $1M | $455.0K | $324.0K | $207.0K | $53.0K | $17.0K | $0 | |
| Net Income | $31M | $30M | $22M | $2.0K | $-29M | $-60M | $-76M | $-114M | $-292M | |
| EPS (Basic) | $0.62 | $0.62 | $0.46 | $0.00 | $-0.72 | $-1.52 | $-75595.00 | · | · | |
| EPS (Diluted) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | · | · | · | |
| Shares (Basic) | 50,011,485 | 48,648,701 | 47,134,331 | 44,674,501 | 40,638,852 | 39,576,107 | · | · | · | |
| Shares (Diluted) | 50,653,283 | 49,100,433 | 47,550,852 | 44,929,998 | 40,638,852 | 39,576,107 | · | · | · | |
| EBITDA | $37M | $31M | $33M | $24M | $1M | $-30M | $-39M | $-95M | $-292M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30M | $69M | $85M | $76M | $63M | $85M | $60M | $108M | $82M | |
| Short-term Investments | $68M | $32M | $11M | $5M | $19M | $8M | $52M | $57M | · | |
| Receivables | $54M | $32M | $48M | $40M | $33M | $26M | $29M | $21M | $10M | |
| Inventory | $6M | $9M | $7M | $5M | $7M | $3M | $3M | $3M | $2M | |
| Prepaid Expense | $4M | $6M | $4M | $6M | $9M | $11M | $13M | $12M | $13M | |
| Other Current Assets | $256.0K | $91.0K | $912.0K | $2M | $447.0K | $4M | $323.0K | $2M | · | |
| Current Assets | $163M | $148M | $156M | $134M | $140M | $146M | $166M | $203M | $106M | |
| PP&E (Net) | $187.0K | $515.0K | $855.0K | $1M | $2M | $2M | $3M | $4M | $4M | |
| PP&E (Gross) | $5M | $8M | $9M | $9M | $9M | $9M | $9M | $9M | $9M | |
| Accum. Depreciation | $5M | $8M | $8M | $7M | $7M | $6M | $6M | $5M | $4M | |
| Intangibles | $41M | $51M | $61M | $71M | $66M | $74M | $40M | $44M | $48M | |
| Total Assets | $216M | $213M | $231M | $222M | $227M | $244M | $235M | $259M | $166M | |
| Accounts Payable | $5M | $6M | $7M | $6M | $11M | $12M | $19M | $21M | $28M | |
| Accrued Liabilities | $50M | $37M | $53M | $53M | $93M | $61M | $69M | $46M | $31M | |
| Current Liabilities | $81M | $96M | $99M | $77M | $110M | $114M | $91M | $67M | $58M | |
| Capital Leases | $5M | $1M | $7M | $12M | $16M | $20M | $23M | · | · | |
| Other Non-current Liabilities | $0 | $121.0K | $121.0K | · | · | · | · | · | · | |
| Total Liabilities | $86M | $121M | $177M | $200M | $229M | $250M | $217M | $225M | $112M | |
| Long-term Debt | $23M | $68M | $102M | $102M | $102M | $84M | $95M | $152M | $48M | |
| Total Debt | $23M | $67M | $100M | $98M | $97M | $98M | · | · | · | |
| Common Stock | $5.0K | $5.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.28B | $-1.31B | $-1.35B | $-1.37B | $-1.37B | $-1.34B | $-1.28B | $-1.20B | $-1.09B | |
| AOCI | $36.0K | $6.0K | $-4.0K | $0 | $-2.0K | $0 | $62.0K | $-12.0K | · | |
| Stockholders' Equity | $130M | $92M | $53M | $22M | $-2M | $-6M | $17M | $34M | $53M | |
| Liabilities + Equity | $216M | $213M | $231M | $222M | $227M | $244M | $235M | $259M | $166M | |
| Shares Outstanding | 50,408,023 | 49,105,834 | 47,646,787 | 46,345,660 | 41,175,507 | 40,086,387 | 39,203,304 | 38,325,037 | 37,594,851 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11M | $12M | $12M | $10M | $11M | $10M | $8M | $7M | $3M | |
| Stock-based Comp | $7M | $8M | $10M | $12M | $33M | $37M | $57M | $87M | $109M | |
| Deferred Tax | $3M | $-7M | $0 | $0 | · | · | · | · | · | |
| Amort. of Intangibles | $10M | $10M | $8M | $8M | $8M | $6M | $4M | $4M | $2M | |
| Operating Cash Flow | $42M | $39M | $27M | $-16M | $21M | $773.0K | $22M | $-24M | $-172M | |
| CapEx | $71.0K | $56.0K | $140.0K | $0 | $0 | $46.0K | $306.0K | $439.0K | $431.0K | |
| Investing Cash Flow | $-36M | $-20M | $-19M | $7M | $-11M | $33M | $5M | $-58M | $-15M | |
| Debt Issued | · | · | · | · | · | · | $25M | $105M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $25M | $105M | $50M | |
| Financing Cash Flow | $-45M | $-34M | $0 | $12M | $-32M | $-10M | $-67M | $108M | $75M | |
| Net Change in Cash | $-40M | $-15M | $8M | $4M | $-22M | $24M | $-40M | $27M | $-113M | |
| Taxes Paid | $1M | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $42M | $39M | $27M | $-16M | $21M | · | · | $-25M | $-173M | |
| Levered FCF | · | · | $14M | $-16M | $8M | · | · | · | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% | -13.5% | -14.4% | -37.7% | -1056.1% | |
| Net Margin | 13.6% | 13.1% | 9.2% | 0.00% | -11.5% | -26.7% | -27.8% | -45.2% | -1054.6% | |
| Pretax Margin | 15.7% | 10.5% | 9.6% | 0.20% | -11.4% | -26.6% | · | · | · | |
| EBITDA Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% | -13.5% | -14.4% | -37.7% | -1056.1% | |
| ROA | 14.5% | 13.6% | 9.5% | 0.00% | -12.4% | -25.0% | -30.6% | -53.5% | -139.6% | |
| ROE | 26.5% | 37.1% | 46.8% | 0.01% | 435.8% | 1873.7% | -436.4% | -283.2% | -221.9% | |
| ROIC | 21.2% | 24.4% | 20.3% | 0.09% | 1.4% | -33.0% | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 1.5 | 1.6 | 1.7 | 1.3 | 1.3 | 1.8 | 3.0 | 1.8 | |
| Quick Ratio | 1.9 | 1.4 | 1.4 | 1.6 | 1.0 | 1.0 | 1.5 | 2.8 | 1.6 | |
| Debt / Equity | 0.2 | 0.7 | 1.9 | 4.5 | -39.7 | -16.5 | · | · | · | |
| LT Debt / Equity | 0.0 | 0.2 | 1.2 | 4.5 | -39.7 | -14.1 | · | · | · | |
| Interest Coverage | · | · | 2.4 | 2.0 | 0.1 | -2.2 | -2.6 | -8.6 | -406.1 |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 1.0 | 1.0 | 1.0 | 1.1 | 0.9 | 1.1 | 1.2 | 0.1 | |
| Inventory Turnover | 8.2 | 8.2 | 10.8 | 9.5 | 12.1 | · | · | 14.9 | 5.5 | |
| Receivables Turnover | 5.3 | 5.8 | 5.3 | 6.3 | 8.7 | 8.3 | 11.0 | 16.5 | 5.7 |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.59 | $1.88 | $1.12 | $0.52 | $-0.06 | $-0.15 | $0.45 | $0.90 | $1.42 | |
| Revenue / Share | $4.51 | $4.69 | $4.96 | $5.08 | · | · | · | · | · | |
| Cash Flow / Share | $0.83 | $0.79 | $0.57 | $-0.35 | · | · | · | · | · | |
| Cash / Share | $0.59 | $1.41 | $1.78 | $1.85 | $1.57 | $2.13 | $1.53 | $2.83 | $2.17 | |
| EPS (TTM) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | · | · | · |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.91% | -2.2% | 3.3% | -9.9% | 12.5% | · | · | · | · | |
| Revenue CAGR 3Y | 0.05% | -3.1% | 1.5% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 0.29% | · | · | · | · | · | · | · | · | |
| EPS YoY | -1.6% | 37.8% | · | · | · | · | · | · | · | |
| Net Income YoY | 2.8% | 40.2% | 1079450.0% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 2396.3% | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $228M | $230M | $236M | $228M | $253M | $225M | $272M | $251M | $28M | |
| Net Income TTM | $31M | $30M | $22M | $2.0K | $-29M | $-60M | $-76M | $-114M | $-292M | |
| Market Cap | $300M | $150M | $206M | $174M | $122M | $411M | $343M | $780M | $3.72B | |
| Enterprise Value | $225M | $116M | $210M | $191M | $137M | $416M | · | · | · | |
| P/E | 9.8 | 4.9 | 9.6 | · | -4.2 | -6.8 | · | · | · | |
| P/S | 1.3 | 0.6 | 0.9 | 0.8 | 0.5 | 1.8 | 1.3 | 3.1 | 134.2 | |
| P/B | 2.3 | 1.6 | 3.9 | 8.1 | -49.8 | -69.1 | 19.6 | 22.7 | 69.7 | |
| P / Tangible Book | 3.4 | 3.7 | · | · | · | · | · | · | · | |
| P / Cash Flow | 7.2 | 3.8 | 7.6 | -11.0 | 5.9 | 532.1 | 15.3 | -32.4 | -21.5 | |
| P / FCF | 7.2 | 3.9 | 7.7 | -11.0 | 5.9 | · | · | -31.8 | -21.5 | |
| EV / EBITDA | 6.0 | 3.7 | 6.4 | 8.1 | 106.1 | -13.7 | · | · | · | |
| EV / FCF | 5.4 | 3.0 | 7.8 | -12.1 | 6.6 | · | · | · | · | |
| EV / Revenue | 1.0 | 0.5 | 0.9 | 0.8 | 0.5 | 1.8 | · | · | · | |
| Earnings Yield | 10.2% | 20.3% | 10.4% | 0.00% | -23.7% | -14.8% | · | · | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $45M | $75M | $54M | $52M | $46M | $59M | $81M | $47M | $44M | $72M | $56M | $55M | $53M | $66M | $57M | |
| Cost of Revenue | $12M | $10M | $23M | $12M | $12M | $11M | $14M | $29M | $11M | $11M | $24M | $13M | $12M | $13M | $17M | $12M | |
| SG&A Expense | $18M | $18M | $18M | $17M | $18M | $18M | $17M | $17M | $25M | $22M | $20M | $23M | $24M | $22M | $25M | $24M | |
| Operating Expenses | $49M | $49M | $58M | $45M | $46M | $42M | $46M | $58M | $49M | $46M | $57M | $48M | $50M | $48M | $56M | $55M | |
| Operating Income | $8M | $-4M | $17M | $10M | $7M | $4M | $13M | $22M | $-2M | $-2M | $15M | $9M | $5M | $4M | $10M | $2M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $3M | · | $3M | $3M | $3M | · | $3M | |
| Interest Income | $831.0K | $1M | $977.0K | $1M | $956.0K | $1M | $1M | $1M | $1M | $972.0K | $719.0K | $689.0K | $660.0K | $537.0K | $519.0K | $216.0K | |
| Other Non-op | $9.0K | $130.0K | $143.0K | $115.0K | $410.0K | $359.0K | $268.0K | $347.0K | $156.0K | $91.0K | $641.0K | $74.0K | $86.0K | $-42.0K | $-204.0K | $64.0K | |
| Pretax Income | $8M | $-3M | $17M | $9M | $6M | $3M | $12M | $21M | $-4M | $-5M | $13M | $6M | $2M | $2M | $-5M | $-293.0K | |
| Income Tax | · | · | · | · | · | · | $-7M | $291.0K | $378.0K | $220.0K | $536.0K | $213.0K | $187.0K | $147.0K | $294.0K | $67.0K | |
| Net Income | $8M | $-4M | $13M | $9M | $6M | $3M | $19M | $20M | $-5M | $-5M | $12M | $6M | $2M | $1M | $-6M | $-360.0K | |
| EPS (Basic) | $0.16 | $-0.07 | $0.26 | $0.18 | $0.12 | $0.06 | $0.40 | $0.41 | $-0.09 | $-0.10 | $0.26 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 | |
| EPS (Diluted) | $0.16 | $-0.07 | $0.26 | $0.17 | $0.12 | $0.06 | $0.40 | $0.41 | $-0.09 | $-0.10 | $0.25 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 | |
| Shares (Basic) | 50,939,946 | 50,845,130 | · | 50,339,456 | 49,700,217 | 49,595,697 | · | 49,008,464 | 48,292,414 | 48,189,256 | · | 47,520,338 | 46,759,062 | 46,636,083 | · | 45,567,739 | |
| Shares (Diluted) | 52,596,589 | 50,845,130 | · | 50,929,893 | 50,144,704 | 49,906,341 | · | 49,173,361 | 48,292,414 | 48,189,256 | · | 47,819,234 | 47,201,185 | 47,157,904 | · | 45,567,739 | |
| EBITDA | $8M | $-4M | · | $10M | $7M | · | · | $22M | $-2M | $-2M | · | $9M | $5M | $4M | · | $2M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $37M | $36M | $30M | $54M | $55M | $63M | $69M | $67M | $67M | $77M | · | $82M | $60M | $61M | · | $78M | |
| Short-term Investments | $57M | $65M | $68M | $41M | $41M | $30M | $32M | $29M | $30M | $30M | · | $3M | $14M | $10M | · | $0 | |
| Receivables | $34M | $26M | $54M | $34M | $26M | $25M | $32M | $55M | $28M | $25M | · | $29M | $31M | $31M | · | $28M | |
| Inventory | $13M | $9M | $6M | $9M | $9M | $9M | $9M | $3M | $9M | $7M | · | $6M | $8M | $4M | · | $5M | |
| Prepaid Expense | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $3M | $3M | $4M | · | $4M | $5M | $5M | · | $7M | |
| Other Current Assets | $199.0K | $196.0K | $256.0K | $230.0K | $73.0K | $98.0K | $91.0K | $236.0K | $241.0K | $255.0K | · | $2M | $573.0K | $449.0K | · | $4M | |
| Current Assets | $145M | $142M | $163M | $144M | $137M | $133M | $148M | $157M | $138M | $143M | · | $125M | $119M | $112M | · | $122M | |
| PP&E (Net) | $103.0K | $124.0K | $187.0K | $305.0K | $388.0K | $474.0K | $515.0K | $601.0K | $680.0K | $757.0K | · | $907.0K | $977.0K | $1M | · | $1M | |
| PP&E (Gross) | $3M | $3M | $5M | $7M | $8M | $8M | $8M | $9M | $9M | $9M | · | $9M | $9M | $9M | · | $9M | |
| Accum. Depreciation | $3M | $3M | $5M | $7M | $8M | $8M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | $7M | |
| Intangibles | · | · | $41M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $193M | $193M | $216M | $203M | $195M | $196M | $213M | $221M | $205M | $214M | · | $204M | $200M | $196M | · | $199M | |
| Accounts Payable | $3M | $8M | $5M | $6M | $5M | $6M | $6M | $8M | $14M | $9M | · | $5M | $8M | $9M | · | $15M | |
| Accrued Liabilities | $45M | $38M | $50M | $37M | $32M | $27M | $37M | $51M | $39M | $38M | · | $34M | $35M | $34M | · | $40M | |
| Current Liabilities | $50M | $60M | $81M | $83M | $79M | $87M | $96M | $110M | $104M | $98M | · | $67M | $60M | $48M | · | $60M | |
| Capital Leases | $4M | $5M | $5M | $5M | $0 | $0 | $1M | $3M | $4M | $6M | · | $8M | $10M | $11M | · | $13M | |
| Other Non-current Liabilities | · | · | $0 | $0 | $0 | $0 | $121.0K | $121.0K | $121.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $54M | $64M | $86M | $88M | $90M | $99M | $121M | $150M | $156M | $163M | · | $165M | $170M | $170M | · | $177M | |
| Long-term Debt | $0 | $11M | $23M | $34M | $45M | $57M | $67M | $79M | $91M | $102M | · | $102M | $102M | $102M | · | $102M | |
| Total Debt | $0 | $11M | · | $34M | $45M | · | · | $78M | $89M | $100M | · | $99M | $99M | $99M | · | $98M | |
| Common Stock | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | · | $5.0K | $5.0K | $5.0K | · | $5.0K | |
| Retained Earnings | $-1.28B | $-1.29B | $-1.28B | $-1.30B | $-1.31B | $-1.31B | $-1.31B | $-1.33B | $-1.35B | $-1.35B | · | $-1.36B | $-1.36B | $-1.37B | · | $-1.36B | |
| AOCI | $-45.0K | $-31.0K | $36.0K | $19.0K | $-14.0K | $-11.0K | $6.0K | $26.0K | $-32.0K | $-26.0K | · | $-4.0K | $-6.0K | · | · | $0 | |
| Stockholders' Equity | $139M | $128M | $130M | $115M | $105M | $97M | $92M | $71M | $49M | $51M | $53M | $39M | $30M | $26M | $22M | $22M | |
| Liabilities + Equity | $193M | $193M | $216M | $203M | $195M | $196M | $213M | $221M | $205M | $214M | · | $204M | $200M | $196M | · | $199M | |
| Shares Outstanding | 51,102,687 | 50,879,204 | 50,408,023 | 50,384,274 | 49,892,725 | 49,615,174 | 49,105,834 | 49,067,348 | 48,460,120 | 48,214,663 | 47,646,787 | 47,542,790 | 46,947,153 | 46,663,599 | 46,345,660 | 45,608,814 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $2M | $3M | $3M | $3M | |
| Amort. of Intangibles | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $800.0K | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $2M | $15M | $14M | $10M | $14M | $4M | $16M | $11M | $1M | $11M | $10M | $11M | $3M | $3M | $8M | $17M | |
| CapEx | $0 | $0 | $-36.0K | $26.0K | $20.0K | $61.0K | $16.0K | $20.0K | $20.0K | $0 | $45.0K | $27.0K | · | · | $0 | $0 | |
| Investing Cash Flow | $8M | $2M | $-27M | $506.0K | $-11M | $2M | $-2M | $259.0K | $703.0K | $-19M | $-8M | $11M | $-5M | $-17M | $-12M | $8M | |
| Financing Cash Flow | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $0 | $0 | $0 | $0 | $0 | $2M | $-53.0K | |
| Net Change in Cash | $-2M | $7M | $-24M | $-1M | $-8M | $-6M | $2M | $114.0K | $-10M | $-8M | $2M | $22M | $-1M | $-15M | $-2M | $25M | |
| Free Cash Flow | · | $15M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.4% | -8.5% | · | 17.6% | 12.7% | · | · | 27.4% | -4.6% | -5.2% | · | 15.3% | 9.0% | 8.3% | · | 4.2% | |
| Net Margin | 14.5% | -8.4% | · | 16.2% | 11.2% | · | · | 25.2% | -9.6% | -11.0% | · | 10.3% | 3.9% | 2.6% | · | -0.63% | |
| Pretax Margin | 14.6% | -7.6% | · | 17.0% | 11.8% | · | · | 25.6% | -8.8% | -10.5% | · | 10.7% | 4.2% | 2.9% | · | -0.51% | |
| EBITDA Margin | 13.4% | -8.5% | · | 17.6% | 12.7% | · | · | 27.4% | -4.6% | -5.2% | · | 15.3% | 9.0% | 8.3% | · | 4.2% | |
| ROA | 4.2% | -1.9% | · | 4.2% | 2.9% | · | · | 9.6% | -2.2% | -2.4% | · | 2.9% | 1.1% | 0.71% | · | -0.17% | |
| ROE | 6.7% | -3.3% | · | 9.5% | 7.6% | · | · | 37.0% | -11.5% | -12.5% | · | 19.0% | 8.5% | 8.5% | · | -6.4% | |
| ROIC | · | · | · | · | · | · | · | 14.6% | -1.7% | -1.6% | · | 6.0% | 3.5% | 3.2% | · | 2.5% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.9 | 2.4 | · | 1.7 | 1.7 | · | · | 1.4 | 1.3 | 1.5 | · | 1.9 | 2.0 | 2.3 | · | 2.0 | |
| Quick Ratio | 2.6 | 2.1 | · | 1.5 | 1.5 | · | · | 1.4 | 1.2 | 1.3 | · | 1.7 | 1.8 | 2.1 | · | 1.8 | |
| Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.4 | · | · | 1.1 | 1.8 | 2.0 | · | 2.6 | 3.3 | 3.8 | · | 4.4 | |
| LT Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.1 | · | · | 0.5 | 0.9 | 1.1 | · | 2.0 | 2.9 | 3.8 | · | 4.4 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -0.7 | · | 2.6 | 1.5 | 1.3 | · | 0.8 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.3 | · | · | 0.4 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Inventory Turnover | 1.1 | 1.2 | · | 2.0 | 1.4 | · | · | 7.0 | 1.3 | 2.0 | · | 2.4 | 1.7 | 2.4 | · | 2.0 | |
| Receivables Turnover | 1.9 | 1.7 | · | 1.2 | 1.9 | · | · | 1.9 | 1.6 | 1.6 | · | 2.0 | 1.7 | 1.8 | · | 2.2 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.71 | $2.52 | · | $2.29 | $2.10 | · | · | $1.45 | $1.00 | $1.06 | · | $0.81 | $0.65 | $0.55 | · | $0.49 | |
| Revenue / Share | $1.07 | $0.88 | · | $1.07 | $1.05 | · | · | $1.64 | $0.97 | $0.91 | · | $1.17 | $1.16 | $1.12 | · | $1.25 | |
| Cash Flow / Share | · | $0.30 | · | · | · | · | · | · | · | $0.23 | · | · | · | $0.06 | · | · | |
| Cash / Share | $0.71 | $0.71 | · | $1.06 | $1.10 | · | · | $1.37 | $1.39 | $1.59 | · | $1.72 | $1.28 | $1.32 | · | $1.71 | |
| EPS (TTM) | $0.52 | $0.48 | · | $0.75 | $0.99 | $0.28 | · | $0.47 | $0.18 | $0.32 | · | $0.08 | $-0.05 | $0.11 | · | $0.22 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $231M | $227M | · | $212M | $238M | $217M | · | $244M | $219M | $227M | · | $229M | $230M | $235M | · | $218M | |
| Net Income TTM | $27M | $24M | · | $37M | $48M | $14M | · | $23M | $9M | $15M | · | $4M | $-2M | $5M | · | $10M | |
| Market Cap | $414M | $325M | · | $268M | $171M | · | · | $125M | $158M | $256M | · | $125M | $166M | $144M | · | $108M | |
| Enterprise Value | $321M | $235M | · | $207M | $120M | · | · | $106M | $150M | $248M | · | $139M | $190M | $172M | · | $128M | |
| P/E | 15.6 | 13.3 | · | 7.1 | 3.5 | 10.6 | · | 5.4 | 18.1 | 16.6 | · | 32.9 | -70.6 | 28.1 | · | 10.8 | |
| P/S | 1.8 | 1.4 | · | 1.3 | 0.7 | · | · | 0.5 | 0.7 | 1.1 | · | 0.5 | 0.7 | 0.6 | · | 0.5 | |
| P/B | 3.0 | 2.5 | · | 2.3 | 1.6 | · | · | 1.8 | 3.3 | 5.0 | · | 3.2 | 5.5 | 5.6 | · | 4.9 | |
| P / Tangible Book | 3.0 | 2.5 | · | 2.3 | 1.6 | 1.5 | · | 1.8 | 3.3 | 5.0 | · | 3.2 | 5.5 | 5.6 | · | 4.9 | |
| P / Cash Flow | · | 21.1 | · | · | · | · | · | · | · | 22.7 | · | · | · | 54.6 | · | · | |
| EV / Revenue | 1.4 | 1.0 | · | 1.0 | 0.5 | · | · | 0.4 | 0.7 | 1.1 | · | 0.6 | 0.8 | 0.7 | · | 0.6 | |
| Earnings Yield | 6.4% | 7.5% | · | 14.1% | 28.9% | 9.5% | · | 18.4% | 5.5% | 6.0% | · | 3.0% | -1.4% | 3.6% | · | 9.3% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $228M | $230M | $236M | $228M | $253M |
| 营业利润率 % | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% |
| 净收入 | $31M | $30M | $22M | $2.0K | $-29M |
| 稀释后每股收益 (EPS) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 0.2 | 0.7 | 1.9 | 4.5 | -39.7 |
| 流动比率 | 2.0 | 1.5 | 1.6 | 1.7 | 1.3 |
| 速动比率 | 1.9 | 1.4 | 1.4 | 1.6 | 1.0 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $42M | $39M | $27M | $-16M | $21M |
机构持有人 (13F) 172 家申报者 · $307.7M 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
172
持有价值
$307.7M
新仓位
22
已退出持仓
15
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 22 (-8 与上一季度对比) | 15 (-1 与上一季度对比) | 60 (-1 与上一季度对比) | 53 (+16 与上一季度对比) | +896K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| ACORN CAPITAL ADVISORS, LLC | $33504835 | 4131299 | 10.89% | 股份 |
| BlackRock, Inc. | $30856410 | 3804736 | 10.03% | 股份 |
| VANGUARD GROUP INC | $22596600 | 3797748 | 7.34% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $18815168 | 2319996 | 6.11% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $14891687 | 1836213 | 4.84% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $14887065 | 1835643 | 4.84% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $14805608 | 1825599 | 4.81% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $12311629 | 1518014 | 4.00% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $10864667 | 1339405 | 3.53% | 股份 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $9113880 | 1123783 | 2.96% | 股份 |
| STATE STREET CORP | $7722058 | 952165 | 2.51% | 股份 |
| KENNEDY CAPITAL MANAGEMENT LLC | $7082082 | 873253 | 2.30% | 股份 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $6420006 | 791616 | 2.09% | 股份 |
| RITHOLTZ WEALTH MANAGEMENT | $6080862 | 749798 | 1.98% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $5881307 | 725192 | 1.91% | 股份 |
| GOLDMAN SACHS GROUP INC | $5426855 | 669156 | 1.76% | 股份 |
| NORTHERN TRUST CORP | $5290851 | 652386 | 1.72% | 股份 |
| Connor, Clark & Lunn Investment Management Ltd. | $5214292 | 642946 | 1.69% | 股份 |
| UBS Group AG | $5164131 | 636761 | 1.68% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $4884166 | 602240 | 1.59% | 股份 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $4318170 | 532450 | 1.40% | 股份 |
| SEI INVESTMENTS CO | $3395406 | 418669 | 1.10% | 股份 |
| GLOBEFLEX CAPITAL L P | $3104565 | 382807 | 1.01% | 股份 |
| Bank of New York Mellon Corp | $2925553 | 360734 | 0.95% | 股份 |
| D. E. Shaw & Co., Inc. | $2565542 | 316343 | 0.83% | 股份 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $2506850 | 309106 | 0.81% | 股份 |
| Invesco Ltd. | $2441127 | 301002 | 0.79% | 股份 |
| Russell Investments Group, Ltd. | $2207818 | 272234 | 0.72% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $2182158 | 269070 | 0.71% | 股份 |
| MORGAN STANLEY | $2154584 | 265670 | 0.70% | 股份 |
| FEDERATED HERMES, INC. | $2033712 | 250766 | 0.66% | 股份 |
| Empowered Funds, LLC | $1786763 | 220316 | 0.58% | 股份 |
| PANAGORA ASSET MANAGEMENT INC | $1764290 | 217545 | 0.57% | 股份 |
| PRUDENTIAL FINANCIAL INC | $1732288 | 213599 | 0.56% | 股份 |
| JPMORGAN CHASE & CO | $1730866 | 211339 | 0.56% | 股份 |
| FMR LLC | $1714811 | 211444 | 0.56% | 股份 |
| STATE OF WISCONSIN INVESTMENT BOARD | $1526562 | 188232 | 0.50% | 股份 |
| FRANKLIN RESOURCES INC | $1395001 | 172010 | 0.45% | 股份 |
| Prospera Financial Services Inc | $1287530 | 158762 | 0.42% | 股份 |
| Haven Private, LLC | $1203913 | 148448 | 0.39% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $1140161 | 140587 | 0.37% | 股份 |
| FIRST TRUST ADVISORS LP | $1055970 | 130206 | 0.34% | 股份 |
| Round Rock Advisors LLC | $1045476 | 128912 | 0.34% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1040051 | 128243 | 0.34% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $1022598 | 126091 | 0.33% | 股份 |
| STRS OHIO | $686106 | 84600 | 0.22% | 股份 |
| Nuveen, LLC | $667437 | 82298 | 0.22% | 股份 |
| EVERGREEN CAPITAL MANAGEMENT LLC | $597960 | 73731 | 0.19% | 股份 |
| CANADA PENSION PLAN INVESTMENT BOARD | $596085 | 73500 | 0.19% | 股份 |
| Trexquant Investment LP | $585729 | 72223 | 0.19% | 股份 |
激进投资者及 5%+ 股东 7 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Alan H. Auerbach ×6 申报 | 2022年12月13日 | · | 初始申报 | 被动投资 | SEC |
| Kapil Munjal 2) | 2011年10月4日 | · | 初始申报 | · | SEC |
| Faraaz Siddiqi 2) | 2011年10月4日 | · | 初始申报 | · | SEC |
| Robert Johnson 2) | 2011年10月4日 | · | 初始申报 | · | SEC |
| Robert Johnson | 2007年11月21日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2007年11月19日 | · | 初始申报 | · | SEC |
| Faraaz Siddiqi | 2007年11月19日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 24 位内幕人士 · 10 位高管 · 12 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Alan H Auerbach | President and CEO | 2026年7月6日 S | 7261671 | 0 | 3 | $-568748 |
| Maximo F Nougues | Chief Financial Officer | 2026年7月6日 S | 230637 | 0 | 3 | $-141703 |
| Douglas M Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | 2026年7月6日 S | 196841 | 0 | 3 | $-122564 |
| Jeffrey Jerome Ludwig | Chief Commercial Officer | 2025年2月7日 A | 156792 | 0 | 0 | $0 |
| Alvin F Wong | Chief Scientific Officer | 2024年2月12日 A | 141241 | 0 | 0 | $0 |
| Richard Paul Bryce | Title of Reporting Person: Chief Medical and Scientific Officer | 2021年4月5日 S | 121662 | 0 | 0 | $0 |
| Steven Lo | Chief Commercial Officer | 2019年7月22日 S | 19557 | 0 | 0 | $0 |
| Charles R Eyler | Title of Reporting Person: Senior Vice President, Finance and Administration and Treasurer | 2019年2月4日 S | 31957 | 0 | 0 | $0 |
| Robert Charnas | The Reporting Person is the Senior Vice President of Regulatory Affairs and Project Management of the Issuer. | 2017年2月16日 A | 26453 | 0 | 0 | $0 |
| Richard Benton Phillips | The Reporting Person is the Interim Head of Regulatory Affairs, Quality Assurance and Pharmacovigilance of the Issuer. | 2016年4月15日 A | · | 0 | 0 | $0 |
| Alessandra Cesano | 董事 | 2026年9月14日 M | 56700 | 0 | 1 | $-566808 |
| Troy Edward Wilson | 董事 | 2026年9月14日 S | 54750 | 0 | 2 | $-123260 |
| Brian M Stuglik | 董事 | 2026年6月12日 S | 113858 | 0 | 1 | $-58320 |
| Allison Dorval | 董事 | 2026年6月12日 S | 90780 | 0 | 1 | $-83592 |
| Adrian Senderowicz | 董事 | 2026年6月12日 S | 27000 | 0 | 1 | $-194400 |
| Jay M Moyes | 董事 | 2026年6月12日 S | 58322 | 0 | 1 | $-158840 |
| MILLER MICHAEL PATRICK | 董事 | 2026年6月11日 A | 81000 | 0 | 1 | $-97200 |
| Ann Calby Miller | 董事 | 2021年6月15日 A | 40732 | 0 | 0 | $0 |
| Hugh O'Dowd | 董事 | 2020年6月9日 A | 25748 | 0 | 0 | $0 |
| Frank Zavrl | 董事 | 2020年6月9日 A | 50993 | 0 | 0 | $0 |
| Thomas Malley | 董事 | 2014年12月15日 A | 156551 | 0 | 0 | $0 |
| Faraaz Siddiqi | · | 2011年10月4日 D | 0 | 0 | 0 | $0 |
| Kapil Munjal | · | 2011年10月4日 D | 0 | 0 | 0 | $0 |
| Robert Andrew Johnson | · | 2011年10月4日 D | 0 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 25 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| ROSC · Lattice Strategies Trust | 0.71% | 55155 NS | 2026年7月31日 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trus... | 0.43% | 177208 SH | 2026年10月2日 | 每日 |
| IWC · iShares Trust | 0.10% | 149805 SH | 2026年9月11日 | 每日 |
| VFQY · VANGUARD WELLINGTON FUND | 0.06% | 34260 SH | 2026年8月19日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.03% | 3640 SH | 2026年10月2日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 32358 SH | 2026年8月19日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 54020 SH | 2026年10月2日 | 每日 |
| IWM · iShares Trust | 0.01% | 1181450 SH | 2026年9月11日 | 每日 |
| RSSL · Global X Funds | 0.01% | 21135 NS | 2026年7月31日 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.01% | 16014 SH | 2026年8月19日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 254380 SH | 2026年8月19日 | 每日 |
| DFAT · Dimensional ETF Trust | 0.01% | 172951 NS | 2026年7月31日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.01% | 170404 NS | 2026年7月31日 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.01% | 81441 NS | 2026年7月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.01% | 3611 NS | 2026年7月31日 | N-PORT |
| IWO · iShares Trust | 0.00% | 67004 SH | 2026年9月11日 | 每日 |
| DCOR · Dimensional ETF Trust | 0.00% | 6348 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 12537 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 15090 NS | 2026年7月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 12376 NS | 2026年7月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 446899 SH | 2026年8月19日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1343121 SH | 2026年8月19日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.00% | 7680 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2979 SH | 2026年8月19日 | 每日 |
| IWN · iShares Trust | · | 357993 SH | 2026年9月11日 | 每日 |
PBYI 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 6 位分析师
卖出
中位数目标
$6.00
-36.9%
0 0.0%
强烈买入
0 0.0%
买入
3 50.0%
持有
1 16.7%
卖出
2 33.3%
强烈卖出
12个月价格目标
1 位分析师 · 2026-08-18平均目标 $6.00 -36.9%
最低$6.00
平均值$6.00
最高$6.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | · |
| ALLO | $314M | -1.6 | -76.8% | · | -59.9% | · |
| PROK | · | · | 1075.0% | -7725.2% | 6.9% | · |
| MNPR | · | · | · | · | · | · |
| CAPR | $1.66B | -12.8 | -11.6% | · | -51.1% | · |
| NGNE | $319M | -4.9 | · | · | -33.6% | · |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | · |
| OVID | $212M | -4.0 | 1181.3% | -240.1% | -18.7% | · |
| ASMB | $539M | -61.8 | 153.5% | -8.5% | -5.5% | · |
| TECX | $391M | -5.2 | · | · | -27.7% | · |
| DMAC | $428M | · | · | · | -78.7% | · |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 6, 2026 申报